
GRCE
Healthcare · Biotechnology · $38.1M market cap
$1.810.00 (0.0%)Nov 13, 4:00 PM EST
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · -1.5% over 90 days · 30-day revisions 0 up, 1 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 12, 2026 | Before the open | — | -0.11 | — |
| Aug 13, 2026 | Before the open | -0.18 | -0.91 | -405.6% |
| Jun 18, 2026 | Before the open | -0.20 | -0.08 | +60.0% |
| Feb 12, 2026 | Before the open | -0.39 | -0.19 | +51.3% |
| Nov 13, 2025 | Before the open | -0.34 | -0.08 | +76.5% |
| Aug 12, 2025 | Before the open | -0.31 | -0.29 | +6.5% |
| Jun 23, 2025 | Time not confirmed | -0.40 | 0.05 | +112.6% |
| Feb 17, 2025 | Time not confirmed | -0.46 | -0.51 | -11.7% |
| Nov 13, 2024 | Before the open | -0.50 | -0.42 | +16.8% |
| Aug 9, 2024 | Before the open | -0.36 | -0.33 | +8.3% |
| Jun 21, 2024 | Time not confirmed | -0.47 | -0.36 | +24.1% |
| Feb 12, 2024 | Before the open | -0.31 | -0.28 | +9.7% |
| Nov 13, 2023 | Before the open | -0.35 | -0.31 |
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to enhance neurological symptoms of Ataxia-Telangiectasia (A-T); and GTX-101,…
| +11.4% |
| Aug 11, 2023 | Before the open | -0.37 | -0.48 | -29.7% |
| Jun 23, 2023 | Time not confirmed | -0.14 | -0.65 | -364.3% |
| Feb 14, 2023 | Before the open | -1.01 | -0.72 | +28.7% |
| Nov 14, 2022 | Time not confirmed | — | -0.11 | — |
| Aug 11, 2022 | Time not confirmed | — | -0.10 | — |
| Jun 21, 2022 | Before the open | -1.00 | -0.31 | +69.0% |
| Feb 14, 2022 | Before the open | -0.62 | -0.69 | -11.3% |
| Nov 10, 2021 | Time not confirmed | — | -0.03 | — |
| Aug 13, 2021 | Time not confirmed | — | -0.08 | — |
| Jun 22, 2021 | Time not confirmed | -0.04 | -0.24 | -500.0% |
| Feb 9, 2021 | Before the open | -2.50 | -1.83 | +26.8% |
| Nov 16, 2020 | Before the open | -3.17 | -3.77 | -18.9% |
| Aug 13, 2020 | Before the open | -3.89 | -3.17 | +18.5% |
| Jun 29, 2020 | Time not confirmed | -0.09 | 0.22 | +344.4% |
| Feb 14, 2020 | Before the open | -4.59 | -8.64 | -88.2% |
| Nov 13, 2019 | Before the open | -5.28 | -16.32 | -209.1% |
| Aug 14, 2019 | Before the open | -8.09 | -7.20 | +11.0% |
| Jun 26, 2019 | Time not confirmed | -0.11 | -0.02 | +79.3% |
| Feb 14, 2019 | Before the open | -4.80 | -3.36 | +30.0% |
| Nov 14, 2018 | Before the open | -6.72 | -29.76 | -342.9% |
| Aug 14, 2018 | Before the open | -12.96 | -11.04 | +14.8% |
| Jun 27, 2018 | Time not confirmed | — | -12.14 | — |
| Feb 14, 2018 | Before the open | -13.44 | -19.20 | -42.9% |